nature portfolio

corresponding author(s):	Conggang Li, Zeting Zhang
Last updated by author(s):	Jul 1, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics		
For all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a Confirmed		
☐ ☐ The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement	
A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
The statist	tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.	
A descript	ion of all covariates tested	
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
A full desc	cription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)	
For null hy Give P value	ypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted es as exact values whenever suitable.	
For Bayesi	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings	
For hierar	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes	
Estimates	of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated	
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.	
Software and	d code	
Policy information a	about <u>availability of computer code</u>	
Data collection	NMR data were collected on Bruker spectrometers operated with TOPSPIN 3.5.	
Data analysis	NMR data were processed with NMRpipe and analyzed with Sparky.	
	g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.	
Data		
All manuscripts m - Accession codes - A description of	about <u>availability of data</u> ust include a <u>data availability statement</u> . This statement should provide the following information, where applicable: s, unique identifiers, or web links for publicly available datasets any restrictions on data availability sets or third party data, please ensure that the statement adheres to our <u>policy</u>	
The data that suppor	t the findings of this study are available from the corresponding authors upon request.	

Field-spe	cific reporting	
Please select the or	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences		
For a reference copy of t	he document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>	
Life scier	ices study design	
All studies must dis	close on these points even when the disclosure is negative.	
Sample size	Dynamic light scattering was used to determine the particle size of liposomes.	
Data exclusions	a was excluded from the analysis.	
Replication	experiments were replicated to assure reproducibility of the results. The number of independent replicates for each experiment are ated in the corresponding figure captions. All attempts at replication were successful.	
Randomization	The experiments were not randomized, conformed to the established procedures in the field.	
Blinding	vas not blind to appoint the investigators during experiments and outcome evaluation, conformed to the established procedures in the d.	
Reporting for specific materials, systems and methods We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Materials & experimental systems Methods n/a Involved in the study Antibodies ChIP-seq Flow cytometry MRI-based neuroimaging MRI-based neuroimaging MRI-based neuroimaging Antibodies		
Antibodies used	Rabbit anti-Cytochrome c Abcam Cat#ab133504/Rabbit anti-Alpha-synuclein Abcam Cat#ab51252, 1:1000 for Western blot	
Validation	Rabbit anti-Cytochrome c Abcam Cat#ab133504/Rabbit anti-Alpha-synuclein Abcam Cat#ab51252, validated by Abcam	
Eukaryotic c	ell lines	
Policy information a	about <u>cell lines</u>	
Cell line source(s)	SK-N-SH cells were purchased from Procell (CL-0214)	

Cell line source(s)

SK-N-SH cells were purchased from Procell (CL-0214)

Authentication

The authenticity of the cells was provided by Procell and the American Type Culture Collection upon purchase.

Mycoplasma contamination

Mycoplasma-free cultures were used for the experiments.

Commonly misidentified lines (See ICLAC register)

No commonly misidentified cells were used.